Nexus Investment Management ULC Has $31.71 Million Stock Holdings in Gilead Sciences, Inc. $GILD

Nexus Investment Management ULC reduced its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 1.5% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 251,016 shares of the biopharmaceutical company’s stock after selling 3,706 shares during the period. Gilead Sciences comprises 4.1% of Nexus Investment Management ULC’s investment portfolio, making the stock its 11th largest holding. Nexus Investment Management ULC’s holdings in Gilead Sciences were worth $31,713,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently made changes to their positions in GILD. Wellspring Financial Advisors LLC raised its holdings in Gilead Sciences by 5.4% in the 2nd quarter. Wellspring Financial Advisors LLC now owns 4,213 shares of the biopharmaceutical company’s stock valued at $532,000 after buying an additional 216 shares during the last quarter. Fortitude Family Office LLC increased its position in Gilead Sciences by 13.7% in the 2nd quarter. Fortitude Family Office LLC now owns 690 shares of the biopharmaceutical company’s stock valued at $87,000 after acquiring an additional 83 shares during the period. Fortem Financial Group LLC raised its stake in shares of Gilead Sciences by 3.5% during the second quarter. Fortem Financial Group LLC now owns 6,585 shares of the biopharmaceutical company’s stock valued at $832,000 after acquiring an additional 221 shares during the last quarter. Mission Wealth Management LP raised its stake in shares of Gilead Sciences by 46.0% during the second quarter. Mission Wealth Management LP now owns 16,879 shares of the biopharmaceutical company’s stock valued at $2,132,000 after acquiring an additional 5,320 shares during the last quarter. Finally, Titleist Asset Management LLC lifted its holdings in shares of Gilead Sciences by 33.9% during the second quarter. Titleist Asset Management LLC now owns 2,409 shares of the biopharmaceutical company’s stock worth $304,000 after purchasing an additional 610 shares during the period. Institutional investors and hedge funds own 83.67% of the company’s stock.

Analyst Ratings Changes

Several brokerages recently weighed in on GILD. Weiss Ratings cut shares of Gilead Sciences from a “buy (b-)” rating to a “hold (c-)” rating in a research note on Tuesday. Barclays cut their target price on Gilead Sciences from $155.00 to $145.00 and set an “equal weight” rating on the stock in a report on Wednesday, July 29th. HSBC upgraded Gilead Sciences from a “hold” rating to a “buy” rating and upped their price target for the company from $133.00 to $155.00 in a research report on Monday, July 6th. Maxim Group raised Gilead Sciences from a “hold” rating to a “buy” rating and set a $165.00 price target for the company in a research note on Wednesday, May 20th. Finally, Leerink Partners downgraded Gilead Sciences from an “outperform” rating to a “market perform” rating and lowered their price objective for the stock from $146.00 to $127.00 in a research report on Tuesday, July 21st. Twenty-four investment analysts have rated the stock with a Buy rating and five have given a Hold rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $158.04.

Key Gilead Sciences News

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Gilead is partnering with Nucleai to deploy AI-powered tissue analytics across its global antibody-drug conjugate programs. The technology could accelerate biomarker discovery, standardize tumor-sample analysis and improve precision-oncology development, potentially strengthening Gilead’s longer-term pipeline. Gilead Sciences Expands ADC Research With AI Tissue Analytics
• Positive Sentiment: Gilead exercised an option to exclusively license a preclinical bispecific program from MacroGenics, triggering a $10 million payment to its partner. The move expands Gilead’s oncology assets and signals continued investment in potential next-generation cancer treatments, although the program remains early stage. MacroGenics Announces $10 Million Milestone Following Gilead License
• Positive Sentiment: Analysts cited a consensus price target of $158.04, indicating potential upside relative to recent trading levels and continued confidence among covering analysts. Gilead Receives $158.04 Consensus Target Price
• Positive Sentiment: Gilead’s second-quarter revenue rose approximately 10% year over year to $7.8 billion and exceeded expectations. The reported loss was primarily affected by an $11.2 billion one-time acquired in-process research and development write-off, while adjusted results were better than consensus. GILD Attractive Biotech Stock With Solid Base Revenue Growth
• Neutral Sentiment: Unusually heavy call-option buying points to increased bullish trading interest, but options activity is speculative and does not by itself change Gilead’s fundamentals.
• Neutral Sentiment: Coverage of Gilead’s second-quarter earnings call may provide additional details on pipeline progress and management priorities, though no specific new financial catalyst was provided in the supplied report. Analyst Questions From Gilead’s Q2 Earnings Call
• Negative Sentiment: Erste Group Bank slightly reduced its FY2026 EPS forecast to a $0.75 loss from a $0.74 loss and trimmed its FY2027 estimate to $9.57 from $9.59. Although the changes are small, they indicate mildly softer expectations and contrast with the $0.50 consensus loss forecast for the current year.

Gilead Sciences Stock Up 0.1%

Shares of NASDAQ:GILD opened at $135.87 on Thursday. The company has a market capitalization of $168.47 billion, a price-to-earnings ratio of -50.89 and a beta of 0.32. The company has a debt-to-equity ratio of 2.03, a current ratio of 1.27 and a quick ratio of 1.09. The business’s 50-day moving average is $129.75 and its 200-day moving average is $136.42. Gilead Sciences, Inc. has a 1 year low of $108.46 and a 1 year high of $157.29.

Gilead Sciences (NASDAQ:GILD) last released its earnings results on Monday, August 3rd. The biopharmaceutical company reported ($6.75) EPS for the quarter, topping the consensus estimate of ($7.25) by $0.50. Gilead Sciences had a negative return on equity of 2.11% and a negative net margin of 10.64%.The business had revenue of $7.80 billion during the quarter, compared to analysts’ expectations of $7.40 billion. During the same quarter last year, the firm posted $2.01 earnings per share. The firm’s revenue was up 10.6% on a year-over-year basis. Equities research analysts predict that Gilead Sciences, Inc. will post -0.53 earnings per share for the current year.

Gilead Sciences Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 29th. Shareholders of record on Tuesday, September 15th will be issued a dividend of $0.82 per share. This represents a $3.28 dividend on an annualized basis and a dividend yield of 2.4%. The ex-dividend date is Tuesday, September 15th. Gilead Sciences’s dividend payout ratio is presently -122.85%.

Insider Transactions at Gilead Sciences

In other news, CEO Daniel Patrick O’day sold 15,000 shares of the firm’s stock in a transaction that occurred on Monday, August 3rd. The shares were sold at an average price of $130.31, for a total transaction of $1,954,650.00. Following the completion of the sale, the chief executive officer owned 592,133 shares of the company’s stock, valued at $77,160,851.23. This trade represents a 2.47% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Andrew D. Dickinson sold 3,000 shares of the business’s stock in a transaction on Monday, June 15th. The shares were sold at an average price of $125.40, for a total transaction of $376,200.00. Following the transaction, the chief financial officer owned 171,646 shares in the company, valued at $21,524,408.40. The trade was a 1.72% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 82,000 shares of company stock valued at $10,641,790 in the last quarter. 0.30% of the stock is currently owned by company insiders.

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.